IONS Ionis Pharmaceuticals Inc.

52.93
-0.54  -1%
Previous Close 53.47
Open 53.2
Price To Book 10.24
Market Cap 7281660024
Shares 137,571,510
Volume 631,636
Short Ratio
Av. Daily Volume 1,106,403

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiation announced October 13, 2017.
IONIS-MAPTRx
Alzheimer's disease
Phase 2 top-line data due 2019.
AKCEA-ANGPTL3-LRx
Rare hyperlipidemias
Phase 2b trial initiation announced January 5, 2017. Top-line data due 2019.
AKCEA-APOCIII-LRx
Hyperlipoproteinemia and established cardiovascular disease
Pivotal trial planned.
IONIS-HTT Rx
Huntington's Disease
Phase 2 data presented at AHA November 2018 - endpoints met.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2b data due mid-2019.
IONIS-FXIRx
End-stage renal disease
CRL issued August 27, 2018.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
Inotersen (IONIS-TTRRx)
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.
Phase 1/2 data possibly due 2H 2018.
IONIS-SOD1Rx
Amyotrophic lateral sclerosis (ALS)
Phase 2 trial to be initiated early 2019.
IONIS-FB-LRx
Geographic Atrophy (GA)
Phase 1b/2 data presented at ESMO 2018. 23% PR/CR.
Durvalumab Plus Danvatirsen
Refractory head and neck cancer

Latest News

  1. Do Analysts See Any Upside for Ionis Stock?
  2. Understanding Ionis Pharmaceuticals’ Operational Performance
  3. Taking Stock of Ionis’s Performance
  4. Should You Buy Ionis Pharmaceuticals, Inc. (IONS)?
  5. The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
  6. Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
  7. Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Expensive For A Reason? A Look At The Intrinsic Value
  8. See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
  9. Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
  10. Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis
  11. First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting
  12. Edited Transcript of IONS earnings conference call or presentation 6-Nov-18 4:30pm GMT
  13. Stocks Not in a Bouncy Mood Yet
  14. Ionis Pharmaceuticals to Present at Jefferies 2018 London Healthcare Conference
  15. 5 Pharma Stocks to Stay Away From
  16. Ionis Pharmaceuticals Collects Royalties -- and Spends It All
  17. Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions

SEC Filings

  1. CT ORDER - Confidential treatment order 181202628
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181162602
  3. 8-K - Current report 181162024
  4. CT ORDER - Confidential treatment order 181143422
  5. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
  6. 8-K - Current report 181131003
  7. 8-K - Current report 181115870
  8. 8-K - Current report 181084567
  9. CT ORDER - Confidential treatment order 181049044
  10. CT ORDER - Confidential treatment order 181036292